Then, an intersection analysis was performed between the top 30 hub genes and 67 prognostic DEGs, five crucial target genes (CD4, ITGAM, ITGB2, CCR5, and HCK) were finally screened out, and HCK was identified as a potential novel prognosis biomarker for AML patients. The gene discussed is CD4; the disease is acute myeloid leukemia.